Scientific Sessions 2024  /  The Future of Lipid Management: Using Lessons From Our Past  /  Gene Therapy and the Potential LDL-Cholesterol "Cure"
Logo

American Heart Association

  113
  0

Final ID:

Gene Therapy and the Potential LDL-Cholesterol "Cure"

  • Parikh, Victoria  ( Stanford University , San Francisco , California , United States )
  • Knowles, Josh  ( Stanford University FALK CVRC , Stanford , California , United States )
  • Khera, Amit  ( Verve Therapeutics , Newton , Massachusetts , United States )
  • Kathiresan, Sekar  ( Verve Therapeutics , Boston , Massachusetts , United States )
    • Author Disclosures:
    Victoria Parikh: DO have relevant financial relationships ; Consultant:BioMarin:Active (exists now) ; Advisor:Constantiam Biosciences:Active (exists now) ; Consultant:Nuevocor:Active (exists now) ; Consultant:Viz.ai:Active (exists now) ; Consultant:Lexeo Therapeutics:Active (exists now) | Josh Knowles: DO have relevant financial relationships ; Consultant:Arrowhead:Active (exists now) ; Consultant:Mammoth:Active (exists now) | Amit Khera: DO have relevant financial relationships ; Employee:Verve Therapeutics:Active (exists now) ; Consultant:Foresite Labs:Active (exists now) ; Consultant:Marea Therapeutics:Active (exists now) ; Consultant:Novartis:Past (completed) ; Individual Stocks/Stock Options:Verve Therapeutics:Active (exists now) | Sekar Kathiresan: DO have relevant financial relationships ; Advisor:Medgenome:Active (exists now) ; Individual Stocks/Stock Options:Relay Therapeutics:Active (exists now) ; Individual Stocks/Stock Options:Maze Therapeutics:Active (exists now) ; Individual Stocks/Stock Options:AntlerA Therapeutics:Active (exists now) ; Consultant:Parameter Health:Active (exists now) ; Consultant:AntlerA Therapeutics:Active (exists now) ; Employee:Verve Therapeutics:Active (exists now) ; Executive Role:Maze Therapeutics:Active (exists now) ; Executive Role:Relay Therapeutics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Future of Lipid Management: Using Lessons From Our Past

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
The Evolution from Statins to Monoclonal Antibodies and Antisense Technology for Lipid Lowering

Michos Erin, Crooke Rosanne, Shapiro Michael

How Do We Get There with Lipid Lowering Therapy? Implementation Insights

Pagidipati Neha

More abstracts from these authors:
Design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol

Vafai Scott, Fiedorek Fred, Karsten Verena, Jensen Chelsey, Falzone Richard, Lister Troy, Stolz Leslie, Khera Amit, Kathiresan Sekar, Bellinger Andrew

Developing single course in vivo gene editing therapies for hyperlipidemia

Kathiresan Sekar, Musunuru Kiran, Ishikawa Kiyotake

You have to be authorized to contact abstract author. Please, Login
Not Available